Status:
RECRUITING
SCG142 TCR-T Cells for Human Papillomavirus-Associated Carcinomas
Lead Sponsor:
The Affiliated Hospital of Qingdao University
Conditions:
Human Papillomavirus Associated Carcinomas
Cervical Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
A multicenter, open, single arm dose escalation and dose expansion phase I study to evaluate the safety, tolerability, and efficacy of SCG142 TCR-T cells in Subjects with advanced HPV associated carci...
Eligibility Criteria
Inclusion
- Key
- Greater than or equal to 18 years of age
- HPV associated carcinomas
- Patients must have at least one measurable lesion defined by RECIST 1.1
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
- Key
Exclusion
- Active or uncontrollable infections or other active major medical illnesses of the cardiovascular, respiratory.
- Patients with active autoimmune diseases.
- Patient has a known active Hepatitis B or Hepatitis C.
- Other severe medical conditions that may limit subject\'s participation in this trial.
Key Trial Info
Start Date :
August 2 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT06544720
Start Date
August 2 2023
End Date
December 31 2026
Last Update
August 9 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The affiliated hosptial of qingdao university
Qingdao, Shandong, China, 266071